Catalyst Wire Dossier Catalyst Wire Dossier

Nivolumab-800CW

Nivolumab · Bristol Myers Squibb
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Nivolumab-800CW, covering 2025-11-21 to 2025-11-21. Get the full timeline:

Most recent: Clinical Trial Update: Optical PD-1 and PD-L1 Imaging in Locally Advanced Esophageal Cancer Using Durvalumab-680LT and Nivolumab-800CW [Phase 1]

See pricing